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Contents
The National Treatment Agency
The National Treatment Agency for Substance
Misuse (NTA) is a special health authority,
created by the Government in 2001 to improve
the availability, capacity and effectiveness of
treatment for drug misuse in England. 
The NTA’s purpose is to work with local
partnerships and health commissioners to
deliver high-quality, effective drug misuse
treatment that improves individuals' physical
and mental health and wellbeing. In turn, this
improves public health, reduces crime and
helps make communities safer.
The Government set the NTA a target of doubling
the number of people in structured treatment
programmes between 1998 and 2008. This has
been exceeded two years ahead of schedule. 
The NTA is now concentrating on the quality
agenda, improving services for people in
treatment and improving outcomes for those
who leave.
The Healthcare Commission
The Healthcare Commission works to promote
improvements in the quality of healthcare and
public health in England and Wales. 
In England, the Commission assesses and
reports on the performance of healthcare
organisations in the NHS and independent
sector, to ensure that they are providing a high
standard of care. It also encourages them to
continually improve their services and the way
they work. 
In Wales, the Healthcare Commission’s role
is more limited. It relates mainly to national
reviews that include Wales and to the yearly
report on the state of healthcare. In this work,
the Commission collaborates closely with
the Healthcare Inspectorate Wales, which
is responsible for the NHS and independent
healthcare in Wales.
The Healthcare Commission aims to:
• safeguard patients and promote continuous
improvement in healthcare services for
patients, carers and the public
• promote the rights of everyone to have
access to healthcare services and the
opportunity to improve their health
• be independent, fair and open in its decision
making, and consultative about its processes.
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Summary
In 1998, the Government introduced its 10-year
drug strategy. This implemented a range of
interventions that concentrated on the most
harmful drugs and on the individuals whose
misuse of drugs and chaotic lifestyle caused the
most harm to society or themselves. A key aspect
of the strategy was to provide more and improved
drug treatment, as this had been shown to be
effective at improving the health and wellbeing
of service users and their families and at
reducing crime related to substance misuse.
As a result, drug treatment services in England
have expanded considerably and have received
substantial investment. Since March 2002,
central government has tripled the amount of
new funding for drug treatment. The number
of people receiving specialist treatment for
drug problems has increased dramatically.
During 2006/2007, there were 195,400 people
in treatment, an increase of 130% on the
1998/1999 baseline of 85,000. 
About this review
Drug treatment is provided by a network of
services, commissioned by local partnerships
of statutory agencies within a particular locality,
rather than being provided by individual
organisations. These networks or ‘local drug
partnerships’ are aligned to local authority
boundaries. There are 149 partnerships in
England that bring together representatives
of local organisations involved in the delivery
of the drug strategy, including primary care
trusts, local authorities, the police and the
probation service.
However, evidence points to a variation in the
quality and availability of care in different areas.
In 2005, the National Treatment Agency for
Substance Misuse (NTA), in partnership with
the Healthcare Commission, embarked on a
joint three-year programme of annual service
reviews as part of an initiative to enhance the
quality, consistency and effectiveness of drug
treatment. Topics for the reviews are:
• Community prescribing services and care
planning and coordination (conducted in
2005/2006)
• Commissioning drug treatment systems and
harm reduction services (this review)
• Diversity and residential services (inpatient
and rehabilitation services) (to be carried out
in 2007/2008).
The service reviews are designed to assess
the provision and commissioning of drug
treatment against key indicators. They provide
a benchmark of the quality of drug treatment
and information on areas of weakness, against
which improvement can be planned.
This report presents the results of the second
in the series of reviews. It was carried out in
2006/2007 and covered commissioning and
systems management of drug treatment and
harm reduction services.
Local drug partnerships received their individual
assessment results in November 2007 while
this report was being prepared, so that they
could begin targeted work to improve their
performance.
Service reviews are based on a standardised
approach and consist of two parts. In the first
part, we assess the performance of all local
drug partnerships. In the second part, we work
with the minority of partnerships (about 10% to
15%) that have the weakest assessment scores
and may require help to develop action plans to
improve their performance. The service reviews
also provide broader information on the progress
being made in drug treatment and on the
priorities that need further development.
For this review the key outcome and quality
measures were developed around two themes:
• Commissioning and systems management:
we reviewed how local drug treatment
partnerships plan, procure and manage
the drug treatment system and manage the
performance of drug treatment services.
Effective commissioning is key to the delivery
of effective drug treatment, to ensure that it
meets local need and is planned, integrated
and strategic.
• Harm reduction services: we reviewed how
local drug treatment partnerships deliver
services that reduce physical harm caused
by drug use. Blood-borne virus rates are
high among drug users, particularly those
who inject drugs. Over 90% of diagnoses of
hepatitis C are associated with injecting drug
use in England and reported drug-related
deaths in the UK are among the highest
in Europe.
Within these two themes, the review
established 10 criteria as indicators of effective
commissioning and harm reduction provision.
We used 45 questions to assess the criteria,
and each question was scored on a scale of: 
• Weak
• Fair
• Good
• Excellent.
These question scores were then used to calculate
criteria level scores and overall scores for each
local drug partnership, using the same scale.
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Summary continued
Overall findings
The review shows that the majority of
partnerships are performing within acceptable
levels, although there was room for improvement.
No partnerships had an overall score of ‘weak’,
but the majority of partnerships had some
shortfalls in key areas. 
The review highlighted the need for local drug
partnerships to develop targeted action plans
to address gaps in the way they commission
services and provide harm reduction services. 
There are clear regional variations in the results.
In general, the north of the country performed
better, having the two top-performing regions
(North East and North West) and none
represented in the bottom five. The North West
region came top against both commissioning
and harm reduction criteria. The South East
region was the lowest performer against both
commissioning and harm reduction criteria.
The top four regions – the North West, the
North East, Yorkshire and London – were the
same for both the commissioning and the harm
reduction elements of the review.
Key messages for commissioning and
systems management
The review provides a helpful picture of the
national strengths and weaknesses in relation
to this area and highlighted some significant
progress:
• Local commissioning partnerships have
developed strong performance management
structures for drug treatment. The contract
monitoring of treatment providers,
performance management of partnerships
and effective data monitoring were all in place
in the majority of local drug partnerships.
Eighty-six per cent of partnerships were
assessed as ‘excellent' against this criterion.
This was attributed to partnerships having
an increased focus on these areas, supported
by relevant guidance, strategies and the work
of NTA’s regional teams in assuring that they
met these standards.
• Drug treatment partnerships have made
significant progress in relation to care
planning and discharge systems. Local
partnerships have shown recent improvement,
particularly in retaining service users in drug
treatment, with 99% achieving or exceeding
70% of their local target.
• There is a good reported standard of
financial management across the sector.
Sixty per cent of local drug partnerships
achieved the maximum score in relation
to financial management.
However, there were also some key areas for
improvement, particularly in relation to the
assessment of need and strategic leadership,
which are essential to effective commissioning
and form the foundation on which an effective
drug treatment system is founded.
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• Many local drug partnerships did not
undertake a systematic assessment of local
need. Over a quarter (26%) of local drug
partnerships did not undertake a needs
assessment to inform their commissioning
of services in 2006/2007.
• The strategic leadership of local drug
partnerships could be enhanced. The review
highlighted a lack of seniority and attendance
of senior representatives from statutory
partners at local drug partnerships' strategic
board meetings. Fifteen per cent of local drug
partnerships had board members that were
below assistant director level. However, the
review did show that service providers and
service users were involved in strategic
planning within local drug partnerships. Ninety
four per cent of local drug partnerships stated
that they held meetings with service users.
• The commissioning of residential and
inpatient services needs to be improved.
The review showed that almost half (48%)
of local drug treatment partnerships did
not commission residential and inpatient
treatment in line with national guidance.
The primary shortfall related to the lack of
requirements for aftercare services in service
contracts, indicating a lack of integrated care.
• There is a need for a continuing focus on
strategic workforce development within
local drug partnerships. Over one third (37%)
of partnerships did not have workforce
development strategies in place. This is a
severe shortfall in the context of the recent
rapid expansion of the sector’s workforce.
Key messages for harm reduction services
The review shows some good progress relating
to harm reduction services:
• Community prescribing services were
assessed as providing a mainly good range of
harm reduction interventions. In particular,
partnerships provided good advice on safer
injecting and preventing overdoses.
• Strategic planning for harm reduction
services was assessed as generally good.
However, in the context of the scale of both
preventable and treatable blood-borne virus
infections and the shortfalls in relation to
testing, vaccination and treatment, additional
action from local drug treatment partnerships
to increase the rates of testing and vaccination
is called for. 
• Local drug partnerships have made
significant progress in developing systems
and protocols to reduce the number of drug-
related deaths but more needs to be done
to reduce these drug-related overdoses even
further. The systems and protocols need to
be drawn together more effectively in multi-
agency strategic plans. Only 68% of local drug
partnerships had a multi-agency strategic
plan for reducing drug-related deaths. 
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Summary continued
However, there are still a number of areas
for improvement on vital issues:
• Vaccination for hepatitis B and testing and
treatment for hepatitis C was not provided
widely enough by local drug treatment
partnerships. Almost all (95.3%) partnerships
offered less than three-quarters (75%) of their
service users a hepatitis B vaccination and 29%
did not have a protocol relating to hepatitis B.
The majority (95.3%) of partnerships reported
that less than 50% of their service users had
a recorded test date for hepatitis C. In the
context that over a third (34%) of all cases
of hepatitis B and over 90% of hepatitis C
diagnoses are associated with injecting drug
use in England, this is a clear national priority.
• Harm reduction interventions were not
provided broadly enough across the treatment
system or sufficiently integrated into it. Just
over a third (37%) of local drug partnerships
did not have access to HIV testing with access
to pre and post-test counselling integrated
with their inpatient drug treatment services.
In addition, 36% of partnerships did not have
hepatitis C testing integrated into their open
access services.
• There is a clear national shortfall in the
provision of out-of-hours needle exchange.
Just under half (44%) of local drug
partnerships scored ‘weak’ in this area.
Only 21% of partnerships opened most of
their needle exchange services on Saturdays
and only 2% opened them on Sundays.
• Nearly half (48%) of the service users
surveyed thought that the harm reduction
services they received were not
comprehensive enough. This related
particularly to wound and abscess dressing,
advice on alcohol and training to deal with
overdose.
Promoting improvements
The review identifies a clear agenda against which
to plan improvement in relation to commissioning
and harm reduction. The review team from the
Healthcare Commission and the NTA supported
approximately 17% of the weakest-performing
partnerships to develop effective action plans,
carrying out 40 strategic meetings and facilitating
18 workshops. The NTA’s regional teams and
strategic health authorities will monitor their
performance against these plans.
It was encouraging that the review also found
widespread improvement against the shortfalls
identified by the first joint service review, which
covered community prescribing and care
planning, particularly in relation to the consistent
use of care plans. This shows that the drug
treatment sector responds positively to the
service reviews and uses them to improve quality.
This review was the second of three joint service
reviews into services for substance misuse
carried out by the Healthcare Commission
and NTA. The final review will be carried out
in 2007/2008 and will look at diversity and
residential services (inpatient and residential
rehabilitation services). Together, all three
reviews will provide a key tool to improve the
provision of drug treatment services to support
the Government’s drug strategy.
The scores achieved by each local drug partnership
are published on the Healthcare Commission’s
website: www.healthcarecommission.org.uk
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Over recent years, the number of people
receiving specialist treatment for drug problems
has increased dramatically. There were 195,464
people receiving treatment in England during
2006/2007 – an increase of 130% on the
1998/1999 baseline of 85,000. This group of
people has clear links to social deprivation,
making this topic a political priority. 
In 2002, the National Treatment Agency for
Substance Misuse (NTA) and the Department of
Health published Models of Care for substance
misuse treatment: promoting quality, efficiency
and effectiveness in drug misuse treatment
services,1 which provides a national framework
for the delivery of services. This guidance was
updated in 2006.2 Models of Care explains how
integrated services should be provided in local
settings. 
The Audit Commission undertook national
studies into the commissioning and provision of
drug treatment in 2002 and 20043, which found
opportunities for improving services. There is
good evidence to show that effective treatment
services are clearly linked to benefits for service
users and the public4. As a result, drug treatment
services have received significant investment
since the introduction of the Government’s 
10-year drug strategy in 1998. Figures from the
NTA’s national database show that the average
national waiting time for drug treatment in
England has fallen from 9.1 weeks in December
2001 to 2.4 weeks in March 2006. In addition,
a new suite of clinical guidelines from the
Department of Health and the National Institute
for Health and Clinical Excellence (NICE) was
published in 20075, which reinforces the view
that much of the current practice in drug
treatment is in line with the evidence.
It was in this context that the NTA and the
Healthcare Commission agreed to work in
partnership on a series of three reviews into
key aspects of services for substance misuse.
The two organisations worked jointly to set up the
process for the reviews and the work is governed
by a memorandum of understanding. The NTA
is a specialist sponsor and the Healthcare
Commission is the inspector and regulator.
Service reviews look at whether healthcare
organisations are improving the care and
treatment they provide to patients. They focus
on particular aspects of healthcare that are
of national importance and where there are
opportunities for organisations to make
substantial local improvements to the quality
of services. Their aim is to encourage each
organisation taking part, or in the review of
substance misuse services, each local drug
partnership, to improve the quality of services
it provides to service users.
The topics for the reviews are:
• Community prescribing services and care
planning and coordination (conducted in
2005/2006)
• Commissioning drug treatment systems and
harm reduction services (this review)
• Diversity and residential services (inpatient
and rehabilitation services) (to be carried out
in 2007/2008).
This work has been groundbreaking in terms
of reviewing and improving the quality of drug
treatment services in England.
This review focuses on two themes:
commissioning drug treatment systems and
harm reduction services. The context of these
themes is outlined as follows.
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Introduction
Commissioning drug treatment systems
There has been unprecedented investment
in drug treatment over the past few years,
combined with the release of a wide range
of guidance documents and new performance
management systems for those who commission
and provide services, which all prioritise drug
treatment. This has resulted in a significant
change in the roles of commissioners and
commissioning groups in a short space of
time. The importance of ensuring the quality
of joint commissioning mechanisms at a local
partnership level is therefore crucial to the
success of the national drug strategy and its
aim of increasing the capacity and quality of
drug treatment. 
Improving commissioning is also a key aspect
of the 2006 treatment effectiveness strategy 2,
which seeks to improve the effectiveness of
drug treatment and the journeys or pathways
taken by service users through treatment. The
treatment effectiveness strategy reinforced the
need for good local systems to assess the needs
of those who misuse drugs, to plan coherent
local drug treatment systems based on local
need and to assess the competencies of local
joint commissioning structures and managers.
This review addressed many of these aspects
of commissioning drug treatment services.
Harm reduction services 
Blood-borne virus (BBV) infections and drug
overdoses account for a significant number of
drug-related deaths and poor health among
drug misusers and particularly drug injectors.
Recent concerns about the rates of BBV infections
and overdoses led the Government to launch a
new Reducing Harm Action Plan in May 2007.6
This review is a key element in the action plan,
as it assesses the performance of each local
drug partnership and seeks to help the poorest
performers to improve, thereby reducing the
number of drug-related deaths in each area.
Drug-related deaths in the UK are among
the highest in Europe. To demonstrate its
commitment to reducing them, the Government
set a national target in 2001 to reduce the
number from 1,538 deaths by 20% by 2004.
Although the previous steep increase in drug-
related deaths during the 1990s was halted,
the target itself was not met. 
The rates of drug-related deaths caused by BBV
infections among drug misusers, particularly
those who inject drugs, have recently increased,
together with the rates of sharing injecting
equipment. 
In 2006, the Health Protection Agency reported
that drug injecting accounts for 5.6% of the
reported diagnoses of HIV. The overall prevalence
of HIV among injecting drug users (IDUs) in
England remains relatively low at one in 50, but
the prevalence in London is much higher at one
in 25. There is concern at the recent increase
in HIV among IDUs outside London, which has
risen by 500% in two years from one in 400
IDUs in 2003, to one in 65 in 2005.7 Homeless
people who inject heroin and crack have higher
rates of infection. 
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Over 90% of hepatitis C diagnoses are associated
with injecting drug use in England. In 2006, the
Health Protection Agency reported that the
current prevalence of hepatitis C among IDUs in
England was 44%: almost one in two IDUs were
infected. There is a wide geographic variation,
ranging from 58% in London to 20% in the
North East. Recent research indicates that those
injecting crack have a much higher prevalence
of hepatitis C (67%) and cohort studies indicate
that the incidence of hepatitis C has recently
increased.7
Over a third (34%) of all cases of hepatitis B in
England are associated with injecting drug use.
The prevalence in England is around 32% but
with wide regional variation (ranging from 32%
in the North West region to 5.5% in Yorkshire).
IDUs who inject crack have a much higher
prevalence of hepatitis B (43%). The rate of
self-reported hepatitis B vaccination has
doubled since 1998, from 25% to 59% in 2005.
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Introduction continued
A three-year action plan to reduce drug-related deaths was introduced in 2001. This was supported
by the Government’s wider drug strategy. However, although data suggested it had a significant
impact on previous trends, the number of drug-related deaths did not reduce by as many as
originally intended and indications show that rates of some blood-borne virus infections may
have begun to rise. Such drug-related deaths and illness associated with these infections are an
enormous waste of life and the Government is determined to reduce the tragic effects suffered
by drug misusers, their friends and families.
The new action plan, launched in May 2007, was designed to be delivered using an integrated
approach at national, regional and local levels. The Department of Health and the NTA are jointly
overseeing its implementation. 
Key aspects of the action plan also feature in this service review on commissioning and harm
reduction. This includes improving surveillance and delivery of harm reduction services by:
• Benchmarking all local drug partnerships in terms of the commissioning and provision of
harm reduction services.
• Developing and implementing local action plans to improve harm reduction in the poorest-
performing areas identified through the joint service review published this year.
• All local drug partnerships working with regional NTA teams to address specific harm
reduction issues identified in the service review.
• Providing guidance to commissioners, including sharing good practice, from sites identified
through the service review (published by the NTA in January 2008).
Department of Health/National Treatment Agency for Substance Misuse, 
Reducing Drug-related Harm: An Action Plan, 2007
Reducing drug-related harm: An action plan
Service reviews are based on a standardised
approach that is information-based and
targeted. The method is designed to encourage
significant improvement without imposing a
large burden on healthcare organisations. 
There are two parts to a service review. Firstly,
we assess the performance of all organisations
taking part. As drug treatment is provided within
partnerships or treatment communities, as
opposed to individual services, we focused on
treatment across these partnerships. These
were defined as local drug partnerships or action
teams (referred to throughout this report as
local drug partnerships).
Secondly, we work with the minority
(approximately 10% to 15%) of organisations
(or systems) that have the weakest assessments
and may require help to develop action plans
to improve their performance. 
The assessment checks performance against
key outcome and quality measures that provide
an indication of the effectiveness of local drug
partnerships. These measures are developed
through engagement with service users, carers,
providers (including clinicians and other experts)
and commissioners of services. The measures
are then cross referenced with national policy,
guidance and standards of good practice.
In the review of substance misuse services,
an overall score of ‘weak’ (1), ‘fair’ (2), ‘good’ (3)
or ‘excellent’ (4) was applied to each local drug
partnership. Ranges of scores were set for each
scoring band. It was possible to achieve a
maximum score of 40 in this review. See the
appendix for a more detailed explanation of
the scoring method.
PCTs are key members of local drug
partnerships. As such, they are given the
same score as that achieved by the local
drug partnership to which they belong. (The
exception to this is for the 11 PCTs whose score
is based on the average aggregated score from
multiple partnerships.)
Criteria used in the review
The assessment framework consisted of 10
criteria (or key headings) across the two themes
(commissioning and systems management and
harm reduction) and 45 questions were clustered
around these criteria, shown in Box 1. Further
detail on the methodology and the development
of the review can be found in the appendix.
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Methodology of the review
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Methodology of the review continued
Theme A: commissioning and systems management
The following criteria were developed to assess the performance of local drug treatment
partnerships on commissioning and systems management:
Local commissioning partnerships:
1. Have formal strategic partnerships with key stakeholders including health, social care,
housing and employment services, drug treatment providers, and local drug users and carers.
2. Have a shared understanding of the local need for drug treatment, based upon annual needs
assessment reports in line with a nationally agreed methodology. This methodology required
the needs assessment to profile the diversity of local need for drug treatment, including
rates of morbidity and mortality (such as infection with blood-borne viruses), the degree
of treatment penetration, and impact of treatment on individuals.
3. Develop local drug treatment system plans annually in line with the Models of Care for
Treatment of Adult Drug Misusers: Update 2006 (NTA, 2006) with focus on reducing harm
to individuals and communities, improving clients’ journeys through treatment, predicting
client flow through local systems and improving the effectiveness of local drug systems.
4. Demonstrate best practice in handling public money, contracting with providers and
monitoring service level agreements.
5. Performance-manage local systems of drug treatment using data and key performance
indicators in partnership with local strategic partners and plans.
6. Are ‘fit for purpose’, have involvement from key stakeholders at an appropriate level of
seniority and ensure commissioners are competent against national quality standards
and other relevant professional frameworks.
Theme B: harm reduction
The following criteria were developed to assess local drug treatment systems’ performance
on the provision of harm reduction services:
7. Service providers deliver harm reduction interventions embedded in the whole treatment system.
8. Service users have prompt and flexible access to needle exchange services, vaccination
and testing and treatment for blood-borne viruses.
9. Service providers take action to reduce the number of drug-related deaths.
10. Service providers have staff competent to deliver effective harm reduction services.
Box 1:  Assessment criteria for the service review
Overall scores
The following analysis of results covers all
149 local drug partnerships that we assessed.
The scores provide a numeric summary of the
performance in each partnership. They show
that while the majority of partnerships are
performing within acceptable levels, there is
some room for improvement. The appendix
describes how we calculated scores for the
overall rating.
Figure 1 shows the distribution of total scores
out of a highest achievable score of 40. The
colours show the thresholds for overall scores
of 1 to 4: ‘fair’ (2), ‘good’ (3) or ‘excellent’ (4).
No local drug partnerships or primary care trusts
(PCTs) scored (1) or ‘weak’ in this review.
Table 1 shows the number and percentage of
overall rating scores awarded to partnerships
and PCTs. Just over a fifth of local partnerships
and PCTs scored ‘fair’, which indicates that
there is some room for improvement. Just over
a third scored ‘excellent’. 
Note: Some PCTs have a different score to the partnership
as they have multiple partnerships within their boundary.
The scores for these PCTs are calculated as the average
of all partnerships covered.
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Key overall results
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Figure 1: Overall distribution of scores
Local drug PCT
partnership
Number % Number % 
Weak 0 0 0 0 
Fair 31 21 34 22
Good 67 45 63 41
Excellent 51 34 55 36
Total 149 100 152 100
Table 1: Distribution of overall ratings
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Key overall results continued
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Figure 2: Distribution of regional scores
Regional scores key
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Note: The regions shown are the nine NTA regions,
which are the same as the Government Offices.
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North East
1 Darlington
2 Durham
3 Gateshead
4 Hartlepool
5 Middlesbrough
6 Newcastle upon Tyne
7 North Tyneside
8 Northumberland
9 Redcar & Cleveland
10 South Tyneside
11 Stockton-on-Tees
12 Sunderland
Yorkshire & The Humber
1 Barnsley
2 Bradford
3 Calderdale
4 Doncaster
5 East Riding of Yorkshire
6 Kingston upon Hull
7 Kirklees
8 Leeds
9 North East Lincolnshire
10 North Lincolnshire
11 North Yorkshire
12 Rotherham
13 Sheffield
14 Wakefield
15 York
East Midlands
1 Derby
2 Derbyshire
3 Leicester
4 Leicestershire
5 Lincolnshire
6 Northamptonshire
7 Nottingham
8 Nottinghamshire
9 Rutland
East of England
1 Bedfordshire
2 Cambridgeshire
3 Essex
4 Hertfordshire
5 Luton
6 Norfolk
7 Peterborough
8 Southend-on-Sea
9 Suffolk
10 Thurrock
South East 
1 Bracknell Forest
2 Brighton & Hove
3 Buckinghamshire
4 East Sussex
5 Hampshire
6 Kent
7 Isle of Wight
8 Medway
9 Milton Keynes
10 Oxfordshire
11 Portsmouth
12 Reading
13 Slough
14 Southampton
15 Surrey
16 West Berkshire
17 West Sussex
18 Windsor & Maidenhead
19 Wokingham
North West
1 Blackburn with Darwen
2 Blackpool
3 Bolton
4 Bury
5 Cheshire
6 Cumbria
7 Halton
8 Knowsley
9 Lancashire
10 Liverpool
11 Manchester
12 Oldham
13 Rochdale
14 Salford
15 Sefton
16 St Helens
17 Stockport
18 Tameside
19 Trafford
20 Warrington
21 Wigan
22 Wirral
West Midlands
1 Birmingham
2 Coventry
3 Dudley
4 Herefordshire
5 Sandwell
6 Shropshire
7 Solihull
8 Staffordshire
9 Stoke-on-Trent
10 Telford and Wrekin
11 Walsall
12 Warwickshire
13 Wolverhampton
14 Worcestershire
South West 
1 Bath & NE Somerset
2 Bournemouth
3 Bristol
4 Cornwall
5 Devon
6 Dorset
7 Gloucestershire
8 North Somerset
9 Plymouth
10 Poole
11 Somerset
12 South Gloucestershire
13 Swindon
14 Torbay
15 Wiltshire
London 
1 Barking  & Dagenham
2 Barnet
3 Bexley
4 Brent
5 Bromley
6 Camden
7 City of London
8 City of Westminster
9 Croydon
10 Ealing
11 Enfield
12 Greenwich
13 Hackney
14 Hammersmith & Fulham
15 Haringey
16 Harrow
17 Havering
18 Hillingdon
19 Hounslow
20 Islington
21 Kensington & Chelsea
22 Kingston upon Thames
23 Lambeth
24 Lewisham
25 Merton
26 Newham
27 Redbridge
28 Richmond upon Thames
29 Southwark
30 Sutton
31 Tower Hamlets
32 Waltham Forest
33 Wandsworth
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Regional variations in results
The map shown in figure 2 illustrates the
location of local drug partnerships within the
nine regions. Regional differences in scores
were clearly evident and are shown in Figure 3. 
The regional variations cover a mean score
range of 2.8 to 3.5. In general, partnerships
in the north of England performed better than
either the midlands or the south of the country, 
having two of the top-performing regions
and no regions represented in the bottom
five. The three northern regions (North West,
North East and Yorkshire) scored an average
of 3.3, compared to a score of 2.9 for the East
Midlands and West Midlands, and an average
score of 3 for London, the South East, South
West and East of England regions. Figures 4a
and 4b show the average scores for regions in
the area of commissioning and harm reduction.
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Key overall results continued
0
North West
North East
London
Yorkshire
South West
West Midlands
East of England
East Midlands
South East
Region
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3.5
3.3
3.2
3.1
3.1
3.0
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2.8
2.8
Figure 3: Mean category score (1 to 4) for each region
The West Midlands, London and the East
Midlands regions all performed better against
the commissioning criteria than against the
harm reduction criteria. The South East region
was the lowest performer against both the
commissioning and harm reduction criteria,
whereas the North West region came top against
both commissioning and harm reduction.
The top four regions are the same for both
commissioning and harm reduction.
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Figure 4a: Average score per region for commissioning (out of a total available score 24)
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Figure 4b: Average score per region for harm reduction (out of a total available score of 16)
The criteria for this theme of the review are
shown in box 1 on page 12. Figure 5 shows
how these fit into the assessment framework.
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Results for commissioning
and systems management 
4. Best practice is followed
in handling public money, 
contracting and SLAs
5. Performance in the 
system is managed
6. Commissioning is fit for 
purpose and competent
1. Strategic partnerships 
are in place
2. Commissioning is 
based on thorough 
needs assessment
3. Treatment systems are 
development in line with 
National Frameworks 
• Recent comprehensive needs assessment
• User satisfaction with system
• Tier 4 commissioning
• Performance vs. targets 
(waiting times/retention/completion) 
• Care planning
• Comprehensive specifications exist for 
all services
• Voluntary organisations treated fairly 
(compact)
• Workforce strategy
• Financial management
• Data quality
• Joint commissioning group or equivalent 
management of treatment plan
• Action vs. previous review
The treatment 
system is managed 
to secure maximum 
outcomes for service 
users and the public
• Seniority and attendance at strategic level
• Service users and carers are involved
• Active involvement of partners
• Training of commissioners (DANOS*)
Improvements in:
• Drug and alcohol use
• Physical health
• Psychological health
• Social functioning
• Criminal involvement
Outcome level Criteria level Question level
Figure 5: The assessment framework for commissioning and systems management 
at both criteria and question level
* Drugs and Alcohol National Occupational Standards
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The strongest commissioning criterion at
a national level related to the performance
management of local drug treatment systems,
where the majority (86%) of local drug
partnerships scored ‘excellent’, only 1% scored
‘fair’ and none scored ‘weak’. The second
strongest criterion was whether local areas
had formal strategic partnerships with key
stakeholders; just over a third (35%) scored
‘excellent’ and 44% scored ‘good’. Another strong
criterion was whether partnerships demonstrated
good financial management and contracting
arrangements, with just over a quarter (27%)
scoring ‘excellent’, just under a third (31%)
scoring ‘good’ and only 2% scoring ‘weak’.
The weakest commissioning criterion at
a national level related to whether local
drug partnerships demonstrated a shared
understanding of the local need for drug
treatment, based upon annual needs
assessments in line with a nationally agreed
methodology. Almost a quarter (23%) of
partnerships scored ‘weak’ and none scored
‘excellent’ on this criterion. The second weakest
criterion related to whether local commissioning
partnerships were judged as being ‘fit for
purpose’ and had the involvement of senior level
key stakeholders and competent commissioners. 
1% 20% 44% 35%
23% 40% 37%
1%
1%
59% 36% 3%
2% 40% 31% 27%
13% 86%
17% 60% 18% 5%
0%
3. Drug treatment
systems
2. Local needs
assessments
1. Strategic drug
partnerships
Weak Fair Good Excellent
10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Score
6. Local commissioning 
functions are fit for 
purpose and competent
5. Performance 
management of local 
drug treatment systems
4. Managing public
finance and contracts
Figure 6: Distribution of scores for each criterion on commissioning and systems management
at a local drug partnership level
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The following section takes each of the
commissioning criteria in turn and looks at
the responses of the local drug partnerships.
Strategic partnerships
Criterion 1: Local commissioning partnerships
have formal strategic partnerships with key
stakeholders including health, social care,
housing and employment services, drug
treatment providers, and local drug users
and carers.
This criterion was chosen because the
involvement of a range of key stakeholders is
crucial to the commissioning of drug treatment.
Drug misusers often have needs that cross
professional boundaries, such as health and
social care. Strategic commissioning and
planning of drug treatment therefore ideally
involves a range of agencies including health
providers, social care providers, housing
providers and the criminal justice system.
In addition, the involvement of service users
and carers in the design and planning of local
services is good practice. This ensures that
services are responsive to the needs of local
drug users and their families. 
Three key questions formed this criterion:
1. What is the level of seniority and attendance
of members of the strategic partnership
board which takes responsibility for
substance misuse?
2. How does the partnership involve service
users and carers in strategic planning?
3. How does the partnership involve service
providers in strategic planning?
Analysis of results in relation to criterion 1:
• The weakest performance in criterion 1
related to the involvement of key statutory
partners in local drug partnerships, with just
over a third (36%) scoring ‘weak’ and almost
half (48%) scoring ‘fair’. In 14.8% of local drug
partnerships, there were board members that
were below assistant director level. In 11.5%
of partnerships, PCT board members did
not attend any meetings, while in 16% of
partnerships, probation representatives
attended only one meeting in a year. 
• The strongest performance for this criterion
related to the involvement of local providers
in local strategic planning where almost four
out of five (79%) partnerships scored ‘excellent’
and only 2% scored ‘weak’ or ‘fair’. Nearly
100% of commissioners stated that they met
and consulted with service providers and
that drug treatment clinicians are invited
to treatment advisory groups or equivalent
groups.
Results for commissioning and systems management continued
Q1 Q2 Q3
Weak 36% 15% 1%
Fair 48% 16% 1%
Good 11% 11% 19%
Excellent 5% 58% 79%
Mean 1.9 3.1 3.8
Table 2: Results of criterion 1 by question
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• The involvement of service users and carers is
very important in planning and commissioning
local drug systems and 58% of local drug
partnerships scored ‘excellent’ for this
question. Ninety-four per cent of local drug
partnerships stated that they held meetings
with service users, in order to invite their input
into the development of annual commissioning
strategies and treatment plans. However, 15%
scored ‘weak’ and 16% scored ‘fair’ on user
and carer involvement, which illustrates some
room for improvement. It was the lack of
reported involvement of carers that generally
lowered partnerships’ overall scores.
Assessment of need
Criterion 2: Local commissioning partnerships
have a shared understanding of the local need
for drug treatment, based upon annual needs
assessments in line with a nationally agreed
methodology.
This criterion was chosen because the
commissioning of effective local drug treatment
systems is heavily dependent upon the local
drug partnership having a clear profile of the
diversity of local need for drug treatment. This
includes rates of illness and death (for example
infection with blood-borne viruses), the degree
of treatment penetration and the impact of
treatment on individuals. Drug problems vary
tremendously between different population
groups and in different localities. It is therefore
very important to adapt local drug services to
meet the needs of the local population and
ensure that there is no differential negative
impact on any individuals or population groups
who need drug treatment. 
Three key questions formed this criterion:
1. Had the partnership carried out or updated a
local needs assessment during the financial
year 2005/2006 to inform the 2006/2007
commissioning?
2. Did the local needs assessment contain the
required elements as defined in national
guidance? 
3. What was the quality of the local needs
assessment and how was the information
used in developing local plans for
commissioning drug treatment systems? 
We asked some of the better performing
local drug partnerships to give feedback on
what they think contributed to their good
performance. The following are some of their
comments relating to strategic partnership:
“The DAT (drug action team) has established
collaborative and strategic partnerships
and regularly reviews the structures and
membership of meetings to ensure we are able
to respond effectively to the changing need
locally and in response to statutory changes.”
Kensington & Chelsea
“The strength of our commissioning strategy
comes from the strength of our partnership
and the involvement and commitment of our
partners, service users, family members and
carers in the joint commissioning group.”
Nottinghamshire
Analysis of results in relation to criterion 2:
• There was clear room for improvement on
the quality of needs assessments with over
a quarter (26%) judged as ‘weak’ and over
half (52%) as ‘fair’. We assessed local drug
partnerships’ needs assessments against
a number of criteria. These included: how
effectively they used available statistics; how
effectively they identified different patterns of
drug use by the different drugs used and the
geography; and the ethnicity, age and gender
of users. Just over a quarter of local drug
partnerships did not score above 45% of
the achievable score in this assessment,
demonstrating significant shortfalls in the
robustness of needs assessments that were
carried out in 2005/2006.
• The question with the most varied response
was whether the local needs assessment was
in line with national guidance. Just under a
third (32%) of local partnerships scored ‘weak’,
just over a third (34%) scored ‘excellent’ and
the remainder scored ‘fair’ or ‘good’. 
• In relation to question 1 (completion of a
needs assessment), 79% of partnerships had
undertaken them in 2005/2006 to inform their
commissioning in 2006/2007 and 21% had not. 
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Results for commissioning and systems management continued
Comments from some better-performing
local drug partnerships on what contributed
to their good performance relating to needs
assessment:
“We have developed an effective needs
assessment process by utilising effective data
analysis capacity within partner agencies such
as the police and probation. Close links to our
partners, particularly within the NHS, made
information collection more straightforward.”
Kirklees
“The Crime and Disorder Partnership,
supported by the public health directorate
of the PCT and the NTA, have developed a
detailed harm reduction needs assessment.
This has been based on the NTA needs
assessment model, together with qualitative
consultation from partner agencies and key
service user forums. We have plans to enhance
this information base on an annual cycle.”
Tameside
Q1 Q2 Q3
Weak 21% 32% 26%
Fair 79% 15% 52%
Good N/A 19% 21%
Excellent N/A 34% 1%
Mean 1.8 2.5 2.0
Table 3: Results of criterion 2 by question
Drug treatment systems
Criterion 3: Local drug treatment system plans
are in line with national frameworks including
Models of Care for Drug Misusers (2006).
This criterion was chosen to indicate whether
drug treatment services are being commissioned
in line with evidence-based guidelines that focus
on reducing harm to individuals and communities,
improving clients’ journeys through treatment,
predicting client flow through local systems and
improving the effectiveness of local drug systems.
These elements are all key indicators of good
quality drug treatment. 
Five key questions formed this criterion:
1. How did the area’s waiting times compare
with national targets?
2. How many service users who started
treatment had a care plan?
3. How did the area’s retention performance
compare with local targets?
4. How did the area’s planned discharge
performance compare with local targets?
5. Were residential and in-patient services
commissioned in line with national guidance?
Analysis of results in relation to criterion 3:
• The strongest national performance was on
the question relating to retention of people
in treatment, where almost all (99%) of local
drug partnerships scored ‘good’ (the highest
score available for this question). This indicates
that in these local drug partnerships, retention
rates meet or exceed 75% of the local targets.
This indicator is part of the public service
agreement (PSA) target on drug treatment, and
relates to the evidence that drug treatment
needs to last three months or more before it
gives long-term benefit to people with severe
drug misuse problems, such as heroin misuse.
Local drug partnerships have focused on
improving retention in drug treatment over the
past few years, and these results have shown
clear improvement in line with local targets. 
• The weakest performance was evident for
question 5, which related to whether local
commissioning for residential and inpatient
treatment was in line with national guidance.
Almost half (48%) of local drug partnerships
scored ‘weak’ and only 6% scored ‘excellent’,
illustrating significant room for improvement.
The main reason for the low scores achieved
by partnerships was because residential and
inpatient service contracts did not include
requirements for aftercare or integrated care
pathways with subsequent interventions.
Added to this, 35% of local drug partnerships
did not have appropriate contracts for these
services in place. 
• In relation to care planning, the results showed
that just over 5% of local drug partnerships
had care plans in place for less than half of
their service users.
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Comment from a better-performing local
drug partnership on what contributed to its
good performance relating to care planning:
“Key to our success is the shared ownership of
the drug treatment system plans and how these
interface with the mainstream agencies and
their strategies, such as families and children’s
services, housing and environmental health.”
Kensington & Chelsea 
Q1 Q2 Q3 Q4 Q5
Weak 21% 28% 1% 7% 48%
Fair 13% 46% 0% 48% 11%
Good 54% 19% 99% 43% 35%
Excellent 11% 7% N/A 2% 6%
Mean 2.5 2.1 3.0 2.4 2.0
Table 4: Results of criterion 3 by question
Commissioning practice
Criterion 4: Local commissioning partnerships
demonstrate best practice in handling public
money, contracting with providers and
monitoring service level agreements.
This criterion was chosen because the significant
investment in local drug treatment systems
requires good governance over discrete and
pooled budgets. In addition, previous reports
noted that contracting and monitoring by
commissioners of drug treatment providers was
seen to be patchy (Audit Commission, 2002),
which resulted in national guidance being issued.
This criterion consisted of four questions:
1. Were detailed service specifications agreed
with service providers for the full range of
services?
2. (Question removed: Were contracts with
voluntary sector providers in line with National
Compact expectations? This question was
removed because the data submitted by
partnerships could not be analysed. The
design of the question did not account for
the possibility that one organisation could
have more than one contract and did not
ask for the total number of contracts. This
resulted in a percentage of returns giving
a greater number of contracts than there
were organisations and as such, rendered
the question impossible to score.)
3. Did the partnership have a workforce
development strategy and a plan to respond
to the needs identified for developing the
workforce?
4. What is the NTA’s assessment of the
partnership’s financial management?
Analysis of results in relation to criterion 4:
• The weakest performance related to
partnerships’ workforce development
strategies. Over a third (37%) of local drug
partnerships scored ‘weak’, showing room for
improvement. These local drug partnerships
did not have workforce development strategies
in place, which is a severe shortfall in the
context of the recent rapid expansion in this
sector’s workforce. However, just under a
third (31%) scored ‘excellent’ and a quarter
scored ‘good’ for this question, illustrating
very variable performance in England. 
• Local drug partnerships generally scored well
on the question of whether local commissioning
partnerships had detailed service specifications,
with over three-quarters (78%) scoring ‘good’ or
‘excellent’. Comprehensive and clear service
specifications are key mechanisms by which
service commissioners can ensure the quality
and drive the performance of drug treatment
services. The high scores for this question
are indicative of significant progress in
commissioning practice and provide a good
foundation for the provision of effective drug
treatment services.
• The question relating to financial management
showed good performance, with 60% of areas
scoring ‘good’ (the maximum score available
for this question) and only 5% scoring ‘weak’. 
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Results for commissioning and systems management continued
Q1 Q2 Q3 Q4
Weak 5% Question 37% 5%
Fair 18% removed 7% 35%
Good 52% 25% 60%
Excellent 26% 31% N/A
Mean 3.0 2.5 2.5
Table 5: Results of criterion 4 by question
Performance management
Criterion 5: Local commissioning partnerships
performance-manage local systems of drug
treatment by using data and key performance
indicators in partnership with local strategic
partners and plans.
This criterion was chosen because drug
treatment is a priority for the Government, which
has set targets as part of the public service
agreement (PSA) on drug treatment. As part of
this mechanism, local drug partnerships have all
set local targets and are performance-managed
by the NTA and regional partners on a quarterly
basis. The quality of the data collected by the
National Drug Treatment Monitoring System
(NDTMS) is therefore critical. 
Active participation of local drug partnerships
in the NTA’s performance monitoring of joint
commissioning and thereby of local providers
is, therefore, very important. 
This criterion consisted of six questions:
1. What was the quality of the data submitted for
NDTMS by structured treatment providers?
2. Does the joint commissioning group receive,
discuss and agree actions in relation to the NTA
quarterly performance management report?
3. What action did the commissioning
partnership take as a result of the 2005/2006
joint improvement review by the Healthcare
Commission and the NTA?
4. What was the content of discussions
between the joint commissioning manager
and the NTA’s regional team at the last
quarterly performance meeting?
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Comments from some better-performing
local drug partnerships on what contributed
to their good performance relating to needs
commissioning practice:
“We have excellent financial support to
the commissioning process from within
the PCT and have an experienced team of
commissioners and a joint commissioning
group attended by senior commissioners
from partner agencies. This enables excellent
forward planning and puts us in a strong
position to address underperformance by
providers and budget problems.”
Kirklees
“The Crime and Disorder Partnership has a
rigorous and detailed process for monitoring
financial and activity-based performance.
This takes place at different levels, against
agreed service level agreements and within
the partnership structure. All partners are
provided with this information at least
quarterly and monthly where required.”
Tameside
5. What was the experience of providers of the
commissioning system?
6. What was the content of discussions during
the course of the last two contract monitoring
meetings between commissioners and
service providers?
Analysis of results in relation to criterion 5:
• Local drug partnerships generally scored
very well on this criterion and on each of the
questions within it. 
• Outstanding performance was evident on
question 4, which related to the content of
discussions between the commissioners and
the NTA regional team at recent quarterly
performance meetings. Over 90% of local
drug partnerships scored ‘excellent’ in this
area. This indicates that the vast majority of
local drug partnerships have robust discussions
about the area’s performance with the NTA
and explore approaches to enhance the
delivery of services.
• For questions 5 and 6, the vast majority
(over 70%) of local drug partnerships scored
‘excellent’ on their relationships with
providers and the content of contract
monitoring meetings. This indicates that the
commissioning relationships and performance
management of treatment services are
generally good and well developed.
• Question 3 asked what action had been taken
as a result of the 2005/2006 joint improvement
review on prescribing services, care planning
and care coordination. Four-fifths (80%) of
local drug partnerships were rated as ‘good’ on
this question and 13% were rated ‘excellent’.
Only 5% of local drug partnerships scored
‘weak’. Eighty per cent of local drug
partnerships had an action plan in place to
address shortfalls revealed by the 2005/2006
review. A further 13% stated that no action
plan was required because best practice was
already in place, or it had been agreed that
no action plan was required as there was
already one in place. The sector has clearly
responded to the shortfalls in service provision
highlighted by the 2005/2006 review and has
undertaken significant planning to address
these.
• The quality of data given to the National Drug
Treatment Monitoring System (NDTMS) was
high, with almost 79% rated as ‘good’ on this
area and 5% rated as ‘excellent’.
• The weakest area in this criterion concerned
whether the joint commissioning group
received, discussed and agreed actions in
relation to the NTA quarterly performance
management report. Eight per cent of local
drug partnerships scored ‘weak’ and a further
3% scored ‘fair’. However, 85% demonstrated
that the report was utilised at a senior
strategic level.
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Results for commissioning and systems management continued
Q1 Q2 Q3 Q4 Q5 Q6
Weak 1% 8% 5% 1% 1% 1%
Fair 5% 3% 2% 1% 9% 14%
Good 79% 85% 80% 6% 19% 15%
Excellent 15% 3% 13% 92% 71% 70%
Mean 3.1 2.8 3.0 3.9 3.6 3.6
Table 6: Results of criterion 5 by question
Commissioning partnerships 
Criterion 6: Local commissioning partnerships
are ‘fit for purpose’, have involvement from
key stakeholders at an appropriate level of
seniority and ensure commissioners are
competent against national quality standards
and other relevant professional frameworks.
This criterion was chosen for a number of
reasons. Firstly local drug partnerships are
more effective if they have the involvement of
senior level stakeholders, particularly in health,
social services, probation and the police. If
drug partnerships have no multi-disciplinary
involvement at a senior level, they are rarely
able to be the influential decision-making
body they were designed to be. Secondly, the
competence of the local joint commissioning
manager or team is crucial to a local drug
partnership’s ability to commission local drug
treatment systems appropriately and in line
with evidence-based guidance. Finally, the
satisfaction of service users was directly
correlated to self-reported outcomes in the
NTA’s surveys of service users from 2005 and
2006, with greater satisfaction associated with
greater reductions in drug misuse and crime. 
Criterion 6 consisted of three questions:
1. Which agencies are actively involved in
implementing commissioning decisions in,
for example, a joint commissioning group
or other equivalent structure?
2. What competencies do commissioners have? 
3. How satisfied overall are service users with
the services provided?
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Comments from some better-performing
local drug partnerships on what contributed
to their good performance relating to
performance management:
“Performance management is embedded
throughout the partnership in Wigan. All
agencies provide local monitoring, which can
be used in conjunction with NDTMS. A local
research and information unit enables
effective performance management across
all partnership plans.”
Wigan
“Robust information systems and analytical
skills within the partnership to interpret the
information, provides effective monitoring.
Together, user feedback and effective
monitoring is the best performance
monitoring tool.”
Nottinghamshire
Analysis of results in relation to criterion 6:
• Local drug partnerships showed considerable
variation in responses to these questions. 
• Question 3 had the lowest mean score of 1.9.
Over a quarter (28%) of local drug partnerships
scored ‘weak’ in terms of whether service
users were satisfied with local services,
around half (52%) scored ‘fair’ and around
a fifth (19%) scored ‘good’. Only 1% scored
‘excellent’. The scores were derived by
combining service users’ responses to 28
questions, which gauged their satisfaction
with a range of different aspects of service
provision. This clearly has implications for
local drug partnerships and needs extensive
planning to improve satisfaction.
• Similar variation was shown for question 1,
concerning which agencies were actively
involved in implementing local commissioning
decisions. Around a third (34%) of partnerships
scored ‘weak’, and a further third (34%)
scored ‘fair’. Just under a third scored ‘good’.
The main reason for these low scores was
that partnership board members involved in
commissioning decisions were not at a senior
manger level. This lack of seniority clearly has
the potential to compromise the effectiveness
of local drug partnerships in addressing drug-
related need.
• Local drug partnerships had the most marked
range of responses to question 2 on the
competency of local commissioners. Just under
a quarter (23%) scored ‘weak’ and a quarter
(25%) scored ‘excellent’; 43% scored ‘fair’ and
9% scored ‘good’. Twenty per cent of local
drug partnerships did not have commissioners
who were competent, through training or
experience, in the following competencies:
drawing up service specifications; inviting
tenders and awarding contracts; monitoring
and evaluating the quality, outcomes and cost-
effectiveness of services and in procuring
services. These are vital competencies required
to commission effective drug treatment systems.
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Results for commissioning and systems management continued
Q1 Q2 Q3
Weak 34% 23% 28%
Fair 34% 43% 52%
Good 31% 9% 19%
Excellent 1% 25% 1%
Mean 2.0 2.3 1.9
Table 7: Results of criterion 6 by question
Comments from some better-performing
local drug partnerships on what contributed
to their good performance relating to being
‘fit for purpose’:
“There is commitment from local senior
managers to ensure the success of the DAAT
(drug and alcohol action team) business plans,
and councillors also take a keen interest in
the work of the DAAT partnership. External
and internal audits are periodically carried
out to ensure there is full understanding of
strengths and weaknesses across the system.”
Kensington & Chelsea 
“Overall improvement in service delivery
is coordinated by a highly integrated
commissioning and performance management
system within the DAT (drug action team).
This provides both strategic direction and
a strong point of reference for providers to
ensure that services meet the population
needs in a coordinated and managed
framework where each service has a clear
understanding of its role and that of others.”
Knowsley
The criteria used to measure performance in
relation to harm reduction services are set out
in Box 1 on page 12. Figure 7 shows how they
fit in the assessment framework.
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Results for harm reduction services
10. Staff are competent to    
deliver effective harm 
reduction services
9. Action is taken to 
reduce the number of 
drug-related deaths
• Strategic commitment
• Needs assessment
• Commissioned across system
• Provided across system
• Service user feedback on harm reduction
• Multi-agency strategy
• Communication of hazards
• System of confidential inquiry
• Protocols and training on overdose 
for key stakeholders
Reduced harm to 
drug misusers
Outcome level Criteria level Question level
8. Service users have prompt 
and flexible access to 
needle exchange services, 
vaccination, testing and 
treatment for BBV
• Proportion of IDUs accessing 
needle exchange
• Opening times (out-of-hours)
• Level of service offered by pharmacist
• Level of hepatitis B virus vaccination
• Response to hepatitis C virus 
• Minimise risk to staff
• Training and experience of staff 
in needle exchanges, pharmacies 
and other services
• User experience of staff
7. Harm reduction is 
embedded in the 
whole system
Figure 7: The assessment framework for harm reduction at both criteria and question level
The strongest criterion related to action taken to
reduce drug-related deaths, with 61% scoring
‘excellent’ and 18% scoring ‘good’. This criterion
looked at: strategic planning to reduce drug-
related deaths, training of ambulance crews in
the use of naloxone (a drug used to counter the
effects of heroin overdose), training of police
custody officers in managing overdose incidents,
and training for parents and carers in dealing
with overdose. Another strong criterion related
to whether the service providers’ staff were
competent to deliver effective harm reduction
services, with 50% scoring ‘good’ and 20%
scoring ‘excellent’.
The weakest criterion for harm reduction was
criterion 8, which relates to access to harm
reduction services, including needle exchange,
harm reduction interventions offered by services,
and blood-borne virus vaccination and testing.
Over half (51%) of local drug partnerships
scored ‘fair’ or ‘weak’ for this criterion. The
second weakest criterion related to whether
harm reduction interventions were embedded
in the whole system, with 33% of partnerships
scoring ‘fair’ or ‘weak’. 
The following section takes each harm reduction
criterion in turn and looks at the responses of
local drug partnerships.
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Results for harm reduction services continued
1%
1%
32% 34% 34%
50% 43% 7%
2% 19% 18% 61%
30% 50% 20%
0%
Weak Fair Good Excellent
10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Score
7. Service providers 
deliver harm reduction 
interventions embedded 
in the whole treatment 
system
8. Service users have prompt 
and flexible access to 
needle exchange services, 
vaccination, testing and 
treatment for BBV
9. Service providers 
take action to reduce 
the number of 
drug-related deaths
10. Service providers have 
staff competent to 
deliver effective harm 
reduction services
Figure 8: Distribution of scores for each criterion on harm reduction
Harm reduction embedded in the
treatment system
Criterion 7: service providers deliver harm
reduction interventions embedded in the whole
treatment system.
This criterion was chosen as it is vital that
interventions to reduce drug-related harm are
a key and integral part of the local treatment
system. They should be accessible to service
users from a range of access points. Their
provision should also be based on a
comprehensive understanding of need, which
informs robust strategic plans. Harm reduction
encompasses a broad range of interventions
and the criterion also assessed the breadth of
local drug partnerships’ provision. The criterion
also assessed how commissioning practice
drove the provision of harm reduction
interventions. Overall, the criterion indicated
the robustness of a local drug partnership’s
approach to harm reduction. 
Criterion 7 was composed of six questions:
1. Does the local drug partnership have a harm
reduction strategy that is informed by internal
and external data?
2. Did the local needs assessment establish the
level of need for harm reduction interventions?
3. Where are harm reduction interventions
provided in the treatment system?
4. Which harm reduction interventions are
provided in community prescribing services?
5. Do service contracts include harm reduction?
6. How comprehensive are harm reduction
interventions as experienced by service users?
Analysis of results in relation to criterion 7:
• Question 3 was the weakest element in
criterion 7, with a mean score of 1.9. The
majority (83%) of partnerships scored ‘fair’ and
15% scored ‘weak’. The results demonstrated
that harm reduction interventions were not
provided broadly enough across the treatment
system. Almost a quarter (22%) of local drug
partnerships did not have a needle exchange
service within their drug treatment services,
with most being located in open access
services. Just over a third (37%) of local drug
partnerships did not have access to HIV testing
with access to pre and post-test counselling
integrated with their inpatient drug treatment
services. Just over a third (36%) of partnerships
did not have hepatitis C testing integrated
into their open access services.
• Question 6 also showed generally weak
performance. It measured service users’
perceptions of how comprehensive harm
reduction interventions were. No partnership
scored ‘excellent’ for this question and
almost half (48%) scored ‘fair’. 
• The strongest performance for this criterion
was on the use of needs assessments to
establish the need for harm reduction services.
Just over half (55%) of local drug partnerships
reported that they used needs assessment data
to inform their commissioning of a range of
six different harm reduction interventions.
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Q1 Q2 Q3 Q4 Q5 Q6
Weak 25% 15% 15% 23% 11% 21%
Fair 9% 7% 83% 7% 29% 48%
Good 17% 23% 2% 20% 39% 31%
Excellent 50% 55% 0% 49% 21% 0%
Mean 2.9 3.2 1.9 2.9 2.7 2.1
Table 8: Results of criterion 7 by question
• The criterion also demonstrated that in
general, community prescribing services
provided a good range of harm reduction
interventions, particularly advice on safer
injecting and preventing overdoses. 
• Strategic planning for harm reduction was
generally good, with half (50%) of the
partnerships scoring ‘excellent’. However, 25%
of local drug partnerships did not have a harm
reduction strategy in place, indicating a lack
of a strategic or planned approach to reduce
drug-related harm in these partnerships.
Access to harm reduction services
Criterion 8: Service users have prompt and
flexible access to needle exchange services,
vaccination, testing and treatment for blood-
borne viruses.
This criterion assessed service users’ access to
a range of harm reduction services. Providing
needle exchange services is vital to reducing
the transmission of blood-borne viruses
and access to these services is key to their
effectiveness. Needle exchange services are
also an effective delivery point for other harm
reduction interventions, including advice,
information, vaccination and testing.
This criterion consisted of six questions:
1. What proportion of injecting drug users
access needle and syringe exchange services?
2. Do dedicated and pharmacy-based needle
and syringe exchange services provide out-
of-hours services to service users?
3. Is harm reduction fully covered in the needle
exchange services?
4. What services do pharmacy-based needle
and syringe exchange services offer to
needle exchange clients?
5. How many service users have been tested
and/or vaccinated against hepatitis B virus?
6. What is the partnership’s response to
hepatitis C & HIV?
32 Improving services for substance misuse
Results for harm reduction services continued
Q1 Q2 Q3 Q4 Q5 Q6
Weak 24% 44% 9% 5% 26% 95%
Fair 14% 44% 4% 9% 70% 3%
Good 14% 12% 28% 30% 0% 1%
Excellent 48% NA 58% 56% 4% 0%
Mean 2.9 1.7 3.4 3.4 1.8 1.1
Table 9: Results of criterion 8 by question
Comments from some better-performing local
drug partnerships on what contributed to their
good performance relating to embedding harm
reduction in the whole treatment system:
“Harm reduction is a priority of all staff within
all commissioned service providers, not just
a specific team. It is also included in all staff
job descriptions including DAAT clinical leads,
commissioners and other officers. We have
a harm reduction strategy and a subgroup of
the joint commissioning group to specifically
focus on harm reduction issues.”
Kirklees
“The partnership in Nottinghamshire has
demonstrated its commitment to a treatment
system underpinned by harm reduction with
the appointment of a harm reduction lead
and a harm reduction champion. Harm
reduction is a standing item on the agenda
for all service reviews. Delivery across all the
objectives within our harm reduction strategy
is dependent upon work with our colleagues
in primary care, public health and the Health
Protection Agency.”
Nottinghamshire
Analysis of results in relation to criterion 8:
• There was a clear shortfall in the provision
of out-of-hours needle exchange, with under
half (44%) of local drug partnerships scoring
‘weak’. Only 1.7% of partnerships opened
most of their services after 7pm and only
21% opened most of their needle exchange
services on Saturdays, with the percentage
falling to 2% on Sundays. This clearly has
access implications for service users who
need injecting equipment during the evenings
and at weekends.
• Question 5 related to policies and service
penetration around testing and vaccination
for hepatitis B. Almost all (95.3%) local drug
partnerships offered less than three-quarters
(75%) of their service users a hepatitis B
vaccination and 29% did not have a protocol
relating to hepatitis B. The majority (70%)
scored ‘fair’ for this question and just over
a quarter (26%) scored ‘weak’. 
• Question 6 related to testing and treatment
for hepatitis C. This is a clear national priority
due to the scale of infection among injecting
drug users. The scores for this question
showed a national shortfall in testing and
treatment provision – no local drug
partnerships scored ‘excellent’.
The question asked what proportion of
injecting service users had been tested
for hepatitis C. The national mean for the
percentage of injecting drug users that had
been tested for hepatitis C was 21.5%. The
vast majority (95.3%) of partnerships reported
that less than 50% of their service users had a
recorded test date for hepatitis C. This question
also asked about hepatitis C testing and
treatment protocols: 65.1% of partnerships
reported that they had these in place.
• In relation to questions 3 and 4, which tested
the range of harm reduction services provided
in pharmacy needle exchanges and specialist
needle exchanges respectively, the results were
very positive with 58% and 56% of local drug
partnerships scoring ‘excellent’. This indicates
that generally, pharmacy and specialist needle
exchanges provide a wide range of harm
reduction information and advice.
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Comments from some better-performing
local drug partnerships on what contributed
to their good performance relating to flexible
access to harm reduction services:
“To promote uptake of our vaccination and
screening programme, our service offers
open access services with harm reduction
nurses available to discuss blood-borne virus
issues with clients at the point of request.”
Tameside
“We have highly accessible needle exchange
outlets offering an effective harm reduction
service. We currently have 43 participating
outlets, including 35 community pharmacies,
and have developed an extensive database
that not only enables accurate data collection,
but also links the outlets to provide an
effective working network.”
Bradford
Reducing drug-related deaths
Criterion 9: Action is taken to reduce the
number of drug-related deaths.
This criterion was chosen as it indicates the
steps that local drug partnerships have put in
place to reduce the number of drug-related
deaths, which is a key principle of national
strategy. Drug-related deaths in the UK are
among the highest in Europe. In 2001 the
Government set a national target to reduce
the number from 1,538 by 20% deaths by 2004.
Although the previous steep rise in drug-
related deaths during the 1990s was halted,
the target itself was not met. 
This criterion consisted of four questions:
1. Does the partnership have a written multi-
agency strategic plan for reducing drug-
related deaths?
2. What proportion of paramedics in emergency
ambulance crews in the area have been
trained in the use of naloxone (a drug used
to counter the effects of heroin overdose)?
3. What proportion of police custody officers
have been trained to deal with overdose
incidents? 
4. How many service users and carers have
been trained during 2005/2006 to deal with
overdose incidents?
Analysis of results in relation to criterion 9:
• This was the strongest-scoring criterion
relating to harm reduction. The mean scores
were above 2 for all questions indicating that,
nationally, local drug partnerships have made
significant progress in developing systems
and protocols to reduce the number of drug-
related deaths. 
• Only 24% of local drug partnerships scored
‘excellent’ for question 1, which related to
having a strategy for reducing the number of
drug-related deaths. Only 68% of local drug
partnerships had a multi-agency strategic
plan for reducing the number of drug-related
deaths and only 64% had a policy for making
confidential enquiries into drug-related deaths.
• Three quarters (74%) of local drug partnerships
scored ‘excellent’ in relation to paramedics
being trained in the use of naloxone. This
indicated that over 60% of paramedics in
those partnerships had been trained and that
ongoing training in the use of naloxone was
available.
• 61% of partnerships scored ‘excellent’ in
relation to police custody officers being trained
to deal with overdose, indicating that in those
partnerships over 60% of police officers had
been trained.
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Results for harm reduction services continued
Q1 Q2 Q3 Q4
Weak 6% 22% 25% 10%
Fair 33% 3% 11% 23%
Good 37% 1% 3% 67%
Excellent 24% 74% 61% N/A
Mean 2.8 3.3 3.0 2.6
Table 10: Results of criterion 9 by question
• With regard to service users and carers being
trained to deal with incidents of overdose, the
majority (67%) scored ‘good’, the maximum
available for this question, indicating that
training was available and that they had an
agreed training policy. Service users and
carers are the people most likely to be first
at the scene of an overdose, therefore
training them to respond appropriately can
reduce the number of drug-related deaths.
Staff competence 
Criterion 10: Staff are competent to deliver
effective harm reduction services
This criterion was chosen because having
competent staff to deliver harm reduction
interventions underpins the effectiveness of
harm reduction services. The ability to recognise
risks and work with service users to change
their behaviour is vital, and the entire initiative
to reduce drug-related harm hinges on the
competence of staff. National strategy has
focused on the competence of staff, particularly
in the context of the rapid expansion of drug
treatment services. 
This criterion consisted of five questions:
1. Are there protocols in place to ensure staff
safety in relation to blood-borne viruses?
2. What training and experience in harm
reduction do staff in non-pharmacy fixed
based needle and syringe exchanges have? 
3. What training and support is provided for
pharmacy staff providing needle exchange
services?
4. Do service users feel respected by pharmacy
staff?
5. What is the level of training or experience
in harm reduction amongst staff working in
specialist community prescribing services?
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Comments from some better-performing
local drug partnerships on what contributed
to their good performance relating to
reducing drug-related deaths:
“We have a clear drug-related deaths process
that is linked to our harm reduction strategy
group, which enables an early response. We
review all local drug-related deaths every six
months and have good links with the coroner.”
Kirklees
“Bradford operates a robust system for
directing the confidential review of drug-
related deaths. The system ensures that all
involved in direct or indirect exposure to death
which may be attributed to the misuse of
drugs are aware of the necessary action which
must be taken and information collected is
used to identify trends and patterns, causes
and outcomes and to promote learning.”
Bradford
Analysis of results in relation criterion 10
• The weakest areas of performance in this
criterion related to whether service users felt
respected by pharmacy staff. Thirty per cent
of local drug partnerships scored ‘weak’
for this question. This was largely because
partnerships have made insufficient progress
in providing training for pharmacy support
staff (as opposed to pharmacists), who have
the most contact with service users. There had
been more progress, however, in relation to
providing training to pharmacists themselves. 
• Another area of weak performance related
to the level of training and experience of staff
working in specialist community prescribing
services on harm reduction interventions,
with 17% scoring ‘weak’ and 26% scoring
‘fair’. The main shortfalls related to: whether
staff were trained in providing treatments
and dressings related to the care of wounds
and lesions; the supply and exchange of
injecting equipment; and supporting
individuals to monitor their own healthcare. 
• However, just over half (52%) of local drug
partnerships scored ‘excellent’ in relation to
protocols to ensure staff safety in relation to
blood-borne viruses, when delivering needle
exchange services, for example.
36 Improving services for substance misuse
Results for harm reduction services continued
Comments from some better-performing
local drug partnerships on what contributed
to their good performance relating to staff
competence to deliver harm reduction services:
“Staff are all well qualified and trained
to deliver harm reduction services. The
partnership has provided training on a
range of issues such as stimulant use, blood-
borne viruses, dual diagnosis, supervised
consumption and risk assessment. The
trainers go to GP surgeries, hospitals,
custody suites, probation, communities
and schools to provide on-site training.”
Harrow
“Training programmes commissioned by the
partnership include harm reduction for all
services in contact with drug using clients,
hepatitis training from our specialist hepatitis/
drug dependency service and specialist training
on injecting related harm for all drug workers.”
Nottinghamshire
Q1 Q2 Q3 Q4 Q5
Weak 6% 13% 17% 30% 17%
Fair 37% 16% 3% 28% 26%
Good 5% 59% 26% 40% 43%
Excellent 52% 12% 55% 1% 14%
Mean 3.0 2.7 3.2 2.1 2.5
Table 11: Results of criterion 10 by question
Local commissioning systems
The service review provides a helpful picture
of both the strengths and weaknesses of
commissioning and systems management.
Overall, the review indicates that the performance
management of local systems and formal
strategic partnerships is functioning well.
Areas for improvement include the development
of local needs assessment and aspects of
delivering drug treatment systems and local
commissioning functions.
The key messages from this review relating
to commissioning are:
• There is evidence that local commissioning
partnerships and the NTA have developed
strong performance management structures
for drug treatment.
• There is a good reported standard of financial
management across the sector.
• Strategic leadership of local drug strategic
partnerships should be strengthened.
Increasing the level of seniority and attendance
of members needs to be considered. The joint
commissioning function would also benefit
from all stakeholders participating more in
implementing commissioning decisions.
• The effective commissioning of a drug
treatment system is dependent on having a
clear profile of the diversity of local needs. The
review demonstrated a need to improve both
the quality of local needs assessment and the
use of information in developing local plans
for commissioning drug treatment systems.
Significant work is now underway to improve
local needs assessments in order to inform
the annual treatment planning process, and
performance in this area is improving.
• Although partnerships are retaining clients
in treatment, the review points to both care
planning and planned discharge as areas
that need continuing improvement. Reducing
unplanned discharges and a continued focus
on care planning are key areas of work for the
NTA and the sector. Improvement in this area is
also likely to improve the levels of satisfaction
of service users reported in the review.
• The review also highlights the need to improve
the commissioning of residential and inpatient
services. The Department of Health and the
NTA have a national programme of work to
build on the capacity and commissioning of
inpatient and residential services. This includes
a programme of capital development, improved
commissioning, including better-developed
regional commissioning, and additional
guidance.
• There needs to be a continuing focus on
strategic workforce development within
partnerships, which focuses on improving the
local provider workforce and the continued
development of the joint commissioning
function. This will be supported by centrally-
commissioned training for joint commissioners
and other strategic partners.
37Improving services for substance misuse
Conclusions and key messages
Harm reduction services
The service review provides a helpful picture
of both the strengths and weaknesses of harm
reduction responses nationally. It indicates that
progress is being made on these vital issues,
but that there are still a number of areas for
improvement. The results showed that harm
reduction interventions were not provided
broadly enough across the treatment system.
The key messages from the review relating
to harm reduction services are:
• Vaccination for hepatitis B and testing and
treatment for hepatitis C are not provided
widely enough by local drug treatment
systems. This is a clear national priority
because of the scale of hepatitis C infection
in England through injecting drug misuse,
and also as hepatitis B is a disease which is
preventable through vaccination programmes.
• Many service users do not perceive their
harm reduction services to be comprehensive
enough. A significant number also feel that
pharmacy staff do not respect them.
• There is a clear national shortfall in the
provision of out-of-hours needle exchange.
• Community prescribing services are, in
general, providing a good range of harm
reduction interventions.
• While strategic planning for harm reduction
services is generally good, the scale of both
preventable and treatable blood-borne virus
infections and the high rates of deaths by
overdose, mean that additional action is needed
by local drug partnerships. The review’s results
on commissioning indicate that this may need
to include improved profiling and assessment
of local needs, particularly of groups more at
risk of contracting blood-borne viruses and
dying through overdose.
The results of this review provide essential
benchmarking and a platform for improvement
around the provision of harm reduction services
as detailed in the Government’s Reducing Drug
Related Harm Action Plan 2007.
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Conclusions and key messages continued
Next steps
The findings of this review, combined with
the findings of the 2005/2006 review on care
planning and community prescribing services,
represent a significant assessment of
performance and identify a clear agenda
against which to plan improvement. 
Local drug partnerships have already used their
individual results to develop action plans to
improve performance. These will be monitored
by the NTA’s regional teams and strategic
health authorities. The Healthcare Commission
and the NTA supported approximately 17% of
the weakest-performing partnerships to develop
effective action plans. The NTA’s regional teams
and regional stakeholders will also monitor
overall improvement in performance on an
ongoing basis through quarterly reviews with
all local drug partnerships. 
In relation to commissioning and systems
management, the key messages of the review
indicate that local drug partnerships should
focus on: strengthening their strategic leadership,
developing a clear understanding of need, and
improving the movement of service users through
the drug treatment system to planned discharge,
supported by effective care planning. 
Other priorities for development are improving
practice in commissioning residential and
inpatient drug treatment services and
underpinning all work with a strategic and
robust approach to workforce development.
In relation to harm reduction, local drug
partnerships must ensure that there are effective
integrated pathways of care into services for
the vaccination, testing and treatment of blood-
borne viruses – particularly for hepatitis C.
Strategic planning regarding harm reduction,
based on effective assessment of local need
and reducing the number of drug-related
deaths, are also areas for some local drug
partnerships to develop. 
Providing harm reduction interventions across
the treatment system is an ongoing priority for
all local drug partnerships and the review
showed that many partnerships do not provide
harm reduction services in all their drug
treatment settings.
This review was the second of three joint reviews
into substance misuse by the Healthcare
Commission and the NTA. The final review will
be undertaken in 2007/2008 and will look at
diversity and residential services (inpatient and
rehabilitation services). An assessment of the
services provided to diverse groups will be vital
to this sector, as substance misuse issues affect
a broad range of communities and people with
diverse needs. Developing and quality-assuring
residential services is also a key developmental
priority for the sector. The Commission for Social
Care Inspection has supported and endorsed
this review, as it will assess the provision of
residential services and social care.
39Improving services for substance misuse
Assessment frameworks
The framework through which performance is
measured is called an assessment framework.
These frameworks are developed by working
with those using and providing services, and
other experts, to ascertain the key features that
are important in delivering quality services to
their service users. An assessment framework
does not measure everything that must be in
place to deliver a quality service. Rather, it
focuses on key features that have a significant
impact on the outcomes for service users.
Assessment frameworks must relate back
to the Department of Health’s Standards for
Better Health (Department of Health, 2004).
By working with the substance misuse sector
(especially service users, commissioners and
service providers), we generated key criteria
and questions that captured the important
distinguishing features for assessing the
performance of services and treatment systems.
This covers both the perspective of service
users and outcomes of services. We needed
to determine what information was required to
answer these questions. When it did not exist
in national datasets, it was collected from each
local drug partnership. We made assessments
of quality based on information collected from
a variety of sources. We used this framework to
make an initial assessment of the performance
of each local drug partnership and participating
healthcare organisation. We collected data
to inform the assessment framework, and
constructed scores for each criterion by
applying pre-determined rules.
Background work
The NTA mapped the existing key standards
used in the substance misuse sector against
the Department of Health’s standards. The
mapping included a range of key standards,
including Models of Care for substance misuse
treatment: promoting quality, efficiency and
effectiveness in drug misuse treatment services,
national occupational standards, commissioning
guidelines, a sector-specific set of standards
developed by the Substance Misuse Advisory
Service (SMAS) on commissioning, and
organisational standards for providers from
Drugscope and Alcohol Concern (QuADS).
This mapping provided a platform to support
the development of criteria and questions.
Engagement with the sector
The NTA established an expert group to support
the development of the 2006/2007 review of
substance misuse. The network included
membership from all relevant professional and
membership bodies, other regulatory bodies,
NHS providers, voluntary sector providers,
service users and carers, and commissioners.
Members of the network were selected by an
application process according to geographical
spread, role, membership of the local networks
(for dissemination and feedback) and relevant
previous experience.
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Appendix: the methodology and development
process of the review
Drafting the assessment framework 
Once we prepared an initial draft of the
assessment framework, we carried out a process
of peer review. This involved dissemination of
the document to several groups of people and
holding a series of meetings to consult on the
document in detail. These groups included:
• the expert group
• staff from the NTA 
• staff from the Healthcare Commission,
including other pilot managers and the
criteria development team
• drug treatment providers and
commissioners. 
Piloting the assessment framework
The initial drafts of the assessment framework,
questionnaires and scoring construction were
created from developmental work carried out
with the expert group and development sites (a
number of partnerships). The draft assessment
framework was then piloted at four sites from
January to early March 2006. The piloting work
involved the sites that completed bespoke
questionnaires, collecting of quantitative data
and in-depth interviews by staff to gather
qualitative information. 
From April to June 2006, the findings from
the pilot were reviewed and used to inform a
redrafting of the assessment framework and
questionnaires. Some of the changes included
clearer wording and adjustments to the questions
or scoring, in particular relating to data for the
commissioning systems. We also produced a
glossary of key words and phrases as a result
of feedback from the pilot.
Final draft documents were further refined by
the NTA, the Healthcare Commission, and the
Department of Health. The final draft was then
checked to make sure that it made sense by a
specially constituted expert group in July 2006.
The framework was finally subject to a modelling
process in the Healthcare Commission to check
data flow and scoring. 
The final assessment framework and allied
documents were signed off by the Healthcare
Commission and the NTA, the Review of
Central Returns (ROCR), the Department of
Health and the Secretary of State for Health.
Data collection and analysis
Bespoke data was collected in October and
November 2006. Other data was also used from
the National Drug Treatment Monitoring System
(NDTMS), the 2006 NTA annual survey of service
users and the annual partnership treatment
plans for 2006/2007.
Data input, analysis and quality assurance took
place until June 2007. Anonymised data was
published in a GEOWISE database in July 2007.
Each local partnership had two weeks to submit
queries and request their scores to be ratified
if they had questions about their results. All
requests for ratifications were answered by the
first week in September and all partnerships
were notified of their updated scores by the
end of September. Final attributed scores
were published in December 2007.
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Assessment framework overview
and scoring
The assessment framework consisted of 10
criteria (or key headings) across the two themes;
45 questions were clustered around these
criteria. Each question was scored on a scale
of 1 to 4 and question scores were aggregated
via a standard set of rules into criteria scores
and then again into overall scores using the
same scale of 1 to 4.
In the review of substance misuse services,
an overall score of ‘weak’ (1), ‘fair’ (2), ‘good’ (3)
or ‘excellent’ (4) was applied to each local drug
partnership. Ranges of scores were set for each
scoring band. In this review a maximum score
of 40 was possible. The overall performance
ranges were:
Excellent: 31 to 40
Good: 25 to 30
Fair: 15 to 24
Weak: 10 to 14
A primary care trust, as a commissioning body,
has significant influence over the performance
of the local drug partnership and was, therefore,
awarded the same score as the local drug
partnership or partnerships. There were 11
PCTs with multiple partnerships. Their score
was based on the average aggregated score
for these partnerships.
The sum of scores for criteria was used to
establish the overall score for each local drug
partnership and the relative position or ranking
of each partnership.
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Appendix: the methodology and development process of the review continued
1. Department of Health and National
Treatment Agency Models of Care for
substance misuse treatment: promoting
quality, efficiency and effectiveness in
drug misuse treatment services, 2002
2. National Treatment Agency Models of
care for treatment of adult drug misusers:
Update 2006, 2006
3. The Audit Commission Changing Habits,
The Commissioning and Management
of Community Drug Treatment Services
for adults, 2002
4. The Audit Commission, Drug misuse 2004,
Reducing the Local Impact, 2004
5. National Treatment Agency (on behalf of
the Department of Health and devolved
administrations) Drug Misuse and
Dependence – UK Guidelines on Clinical
Management, 2007
6. Department of Health/National Treatment
Agency for Substance Misuse, Reducing
Drug-related Harm: An Action Plan,
October 2007
7. Health Protection Agency, Health Protection
Scotland, National Public Health Service
for Wales, CDSC Northern Ireland, and the
CRDHB. Shooting Up: Infections among
injecting drug users in the United Kingdom
2006. London: Health Protection Agency,
October 2007
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